Foreign research reveals the efficacy of inactivated vaccines, high safety, low risk. prevent covid-19 in children up to 90%
Recently, information from the Department of Health Ministry of Public Health in Thailand The cumulative rate of children aged 5-11 who received the first dose is 55.8%, the second dose is 22.1%, and children who have not received the vaccine are 28.7%. have not been vaccinated This may be due to many factors. One of the important factors comes from the fact that parents are still concerned regarding the choice of vaccinations for their children. whether it is a side effect on the health of children following vaccination both short-term and long-term results
including the prophylactic efficacy of the vaccine especially in children with congenital disease that require special surveillance In addition, children who have been exposed to COVID-19 may also be at risk of developing complications following contracting COVID-19, such as Multisystem Inflammatory Syndrome (MIS-C). in Children), which is severe and affects the functioning of the heart and gastrointestinal tract. And there is still the matter of Long COVID symptoms in children that have not been conclusively proven.
Recently, Sinovac Biotech released a study confirming the effectiveness of the “Inactivated Vaccine” in pediatric vaccinations. and is becoming an alternative vaccine that is gaining attention from parents. In addition, the research has shown the results of research studies certifying that inactivated vaccine It is safe for children It is also widely approved for pediatric use in the section titled “Safety and Immune Response to Omicron Virus Species. and primary immune tolerance in children and adolescents After receiving the 3rd dose of CoronaVac vaccine, the study was conducted among 346 children and youth aged 3-17 years.
The study found that the vaccine showed a safe outcome in the sample. as well as building immunity that inhibits the proliferation of the coviral-19 virus Omicron species. In particular, following receiving all three doses, follow-up 28 days following the third dose, 10 and 12 months apart from the second dose, antibody levels were found to protect once morest COVID-19. In addition, the study found that inactivated vaccines cause mild generalized immediate post-injection adverse reactions. (Severity Grade 1) and no long-term serious symptoms were reported following injection. In terms of immunity It was found that the samples had levels of antibody formation. (Seroconversion) once morest the COVID-19 virus original species and omikron strains were at 100% and 90%, respectively, with antibodies protecting once morest the original strain by more than 30 times from pre-vaccination.
In addition, research from Chilean Real-World, Chile, the country where children are vaccinated with lethal vaccination. also show consistent results in the same direction The inactivated vaccine was found to be effective in preventing more than 74.5% of COVID-19 infections in children 6-16 years of age. 91% and 93.8%, respectively, for efficacy once morest Omicron strains. The vaccine was found to prevent 64.6% and 69% of the children aged 3-5 years from hospitalization and severe emergency, respectively.
Inactivated vaccines for children are not new. Previously, inactivated vaccines have played a role in helping to treat disease in children. like polio and influenza It has been proven that it can effectively prevent disease. and no history of serious side effects, both acute and long-term In addition to being used in children Inactivated vaccines are also commonly used in special needs groups such as pregnant women and immunocompromised groups. Because they do not contain the replicating virus, these vaccines themselves became the prototype for the development of inactivated vaccines once morest COVID-19. Children in Thailand include Sinovac Vaccine and Sino Farm. For children aged 6 and over, the Sinovac vaccine, approved for use in juveniles in 14 countries including Chile, Brazil and Hong Kong, has now been distributed to more than 260 million children’s doses worldwide.
refer
[1] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4099431
[2] Jara, Alejandro, et al. “Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study.” (2022). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4035405
[3] Rafael Araos, Alejandro Jara, Eduardo Undurraga et al. Effectiveness of CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak, 15 March 2022, PREPRINT (Version 1) available at Research Square https://doi.org/10.21203/rs.3.rs-1440357/v1
press release
